|What I would hope to achieve as an Ordinary Council Member
It is important to understand the requirements of a diverge and changing ERA-EDTA membership. I would be instrumental in supporting the President of the ERA-EDTA in respect to activities with the National Presidents of all European Nephrology Societies. Visibility, communication, common trunk education and gender aspects are important topics. My research activities in the cardiology and diabetes arena could help to build stronger relationships with other organisations and Societies in respect to pertinent topics.
|Full Name||Prof Christoph Wanner|
|Education||1982: Fellowships at the Universities of Singapore and Internal Medicine in Zürich, Switzerland
1983-1990-1993: Residency and Consultant in Internal Medicine/ Nephrology at the Univ of Freiburg 1991/1993: German Board of Internal Medicine/Nephrology Examination 1992: National Institutes of Health, NHLBI, Molecular Disease Branch, Bethesda, USA
|Career||In 1994 I as was appointed Professor of Medicine and head of the Division of Nephrology, University of Würzburg. In 2003 the Faculty established a Clinical Trial Service Unit at the hospital and I served as director for 6 years.|
|Accomplishments||My clinical and research live is devoted to progression of cardiovascular and kidney disease. Two
major landmark trials were accomplished. The 4D study has stimulated research in the field and has changed the view of how cardiovascular disease is developing and treated in dialysis patients.
Treatment of progression of diabetic and non-diabetic kidney disease with empagliflozin or other
SGLT2 inhibitors may complement one day the treatment with RAS inhibitors. Their definitive proof has to withstand the test of time.
|Publications (peer reviewed publications, first or senior author)
- 5 most important
|Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658 Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248 Wanner C, Amman K, Shoji T. The heart and vascular system in dialysis. Lancet 2016;388:276-284 Wanner C, Inzucchi S, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. New Engl J Med 2016;375:323-334 Wanner C, Lachin JM, Inzucchi SE et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018;137:119-129|
|Awards||1985 Award for Clinical Investigation, American Medical Association 2007 International
Distinguished Medal of the US National Kidney Foudation 2011 Honorary Member, Polish Society of
Nephrology 2012 Doctor honoris causa, Charles University Prague 2016 ERA-EDTA Outstanding
Clinical Contributions to Nephrology.
|Contributions to the ERA-EDTA
and/or to national/ international nephrology
|From the year 2000 onwards, I trained young researchers in courses on “How to write, read and
review a paper”, served as a lecturer in junior scientific masterclasses and Introduction to Medical
Research as well as in many ERA-EDTA Introductory Courses on Epidemiology. I participated in
EBPG and ERBP guideline formation and member of the Board. From 2009 I served as chairman of the ERA-EDTA/ESPN Registry and in 2010 as President of the XLVII ERA-EDTA Congress. I
completed 17 years of service as Subject Editor of NDT.
|Other||My wife Sabine and myself, we have a lovely family with three grown-up boys. In trying to do 10.000 steps per day I am going to hospital by bicycle every day, irrespective of weather conditions. We love to climb mountains.|
How would you rate this page? (from 1 to 5, being 5 the best score)
Comment sent. Thank you for your cooperation.